Cargando…
Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohort with ex...
Autores principales: | Mirabelli, Maria, Chiefari, Eusebio, Tocci, Vera, Puccio, Luigi, Foti, Daniela, Brunetti, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089678/ http://dx.doi.org/10.1210/jendso/bvab048.680 |
Ejemplares similares
-
Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021) -
Early Onset Acceleration of Fetal Growth in Gestational Diabetes Mellitus: Deciding About When and Whom to Screen for Preventing Fetal Macrosomia
por: Mirabelli, Maria, et al.
Publicado: (2021) -
Effects of Evogliptin as Add on in Type 2 Diabetes (T2DM) Subjects Inadequately Controlled With Metformin and Glimepiride Combination
por: Guha, Shaibal
Publicado: (2021) -
Necrotizing Pancreatitis Secondary to Dulaglutide Use
por: Bhat, Salman Zahoor, et al.
Publicado: (2021) -
SAT-LB031 Empagliflozin as an Add-On Medication to Subjects Uncontrolled on DPP4 Inhibitors and Metformin: Real World Data Supporting the Use of Empagliflozin as a Rational Second Add-On in Indian Type 2 Diabetic Patients
por: MS, ANEESH
Publicado: (2019)